Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Oxytocin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 03 Oct 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 07 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.